This study showed in 99 patients with Marfan syndrome that patients responding to losartan therapy with a reduction of the plasma TGF-β level had higher baseline TGF-β levels and a higher aortic root dilatation rate. The gene discussed is TGFB1; the disease is Marfan syndrome.